[The drug arginine aspartate (pargin) in the therapy of hyposomal states].
Arginine aspartate (Pargine), a stimulator of endogenous STH, was given to 13 adolescents with retarded growth resulting from a relative deficiency of STH for 6 mos. Two patients discontinued treatment after 3 mos., two others are still on therapy. In 3 adolescents the rate of growth against a background of therapy was insufficient (1.3 cm over 6 mos.). Six patients demonstrated a positive effect: the rate of growth over 6 mos. was 4.13 +/- 0.39 cm, the basal level of STH increased by 6.3 +/- 2.46 ng/ml. The drug use did not accelerate skeletal differentiation in either of the patients. A conclusion is that the drug can be used to influence growth processes in patients with hyposomal conditions.
Kiseleva
E V
EV
Zarubina
N A
NA
Pankova
S S
SS
Starkova
N T
NT
D000293:Adolescent; D001120:Arginine / Q000627:therapeutic use*; D001224:Aspartic Acid / Q000627:therapeutic use*; D002648:Child; D006130:Growth Disorders / Q000188:drug therapy*; D013006:Growth Hormone / Q000187:drug effects; D006801:Humans; D008297:Male
D001224:Aspartic Acid; D013006:Growth Hormone; D001120:Arginine; C024891:arginine aspartate
Preparat arginina aspartat (parzhin) v terapii giposomal'nykh sostoianiĭ.